Jennifer Marvin-Peek

Oncology
210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

FLT3-directed therapy in acute myeloid leukemia: lessons from the final analysis of LACEWING.

FLT3-directed therapy in acute myeloid leukemia: lessons from the final analysis of LACEWING.

Journal: Haematologica
Published: August 13, 2026

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2026

The Role of Advanced Molecular Diagnostics in Informing Targeted Therapies for AML.

The Role of Advanced Molecular Diagnostics in Informing Targeted Therapies for AML.

Journal: Human pathology
Published: April 20, 2026

Pharmacokinetics, efficacy, and safety of arsenic formulations in acute promyelocytic leukemia treatment.

Pharmacokinetics, efficacy, and safety of arsenic formulations in acute promyelocytic leukemia treatment.

Journal: Expert review of clinical pharmacology
Published: March 30, 2026

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Journal: Cancer
Published: January 28, 2026

Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?

Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 20, 2025

Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML.

Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML.

Journal: American journal of hematology
Published: November 18, 2025

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.

Journal: Blood cancer journal
Published: October 05, 2025

Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies.

Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies.

Journal: HemaSphere
Published: September 14, 2025

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 13, 2025

Central nervous system relapse of core-binding factor acute myeloid leukemia.

Central nervous system relapse of core-binding factor acute myeloid leukemia.

Journal: Leukemia & lymphoma
Published: May 19, 2025
Showing 1-12 of 26

Last Updated: 09/26/2026